Last reviewed · How we verify

Ciclopirox NL — Competitive Intelligence Brief

Ciclopirox NL (Ciclopirox NL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antifungal agent. Area: Dermatology/Infectious Disease.

marketed Topical antifungal agent Fungal cytochrome P450 enzymes (via metal ion chelation) Dermatology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ciclopirox NL (Ciclopirox NL) — Galderma R&D. Ciclopirox is a broad-spectrum antifungal agent that inhibits fungal enzyme systems by chelating polyvalent cations, disrupting cellular respiration and biosynthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ciclopirox NL TARGET Ciclopirox NL Galderma R&D marketed Topical antifungal agent Fungal cytochrome P450 enzymes (via metal ion chelation)
Ciclopirox 8% Ciclopirox 8% MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA marketed Topical antifungal agent Fungal cytochrome P450 enzymes and polyvalent cation-dependent metalloenzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antifungal agent class)

  1. Galderma R&D · 1 drug in this class
  2. MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciclopirox NL — Competitive Intelligence Brief. https://druglandscape.com/ci/ciclopirox-nl. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: